MTSR: Metsera Corp Company Value to Net Income

Symbol and logo of brand Metsera, Inc. (MTSR)

Metsera Inc focuses on developing weight-loss injections, ensuring consistent demand for the therapy. The company's quarterly P/E reflects investor expectations amid fierce competition, with the latest reading standing at -23.20. Balance sheet stability is supported by capital from major venture funds. The active expansion of the pipeline for new metabolism-correcting agents provides access to a global mega-market.

P/E Multiple: Metsera Corp (MTSR) for 11/14/2025 - 11/29/2025

Comprehensive metric breakdowns and analytics for Metsera Corp (MTSR)

- price and consensus price forecast:
Stock Price metsera.com|MTSR - Consensus Target
- market capitalization information:
Market Value Metsera Inc|MTSR - Total Company Value
- balance sheet net asset value indicators:
Accounting Value per Share Metsera|MTSR - Book Capitalization|Market-to-Book Ratio metsera.com|MTSR - Cumulative Company Assets
- company liabilities and liquidity data:
Aggregate Debt to Capital Metsera Inc|MTSR - Long-Term Debt to Capital|Short-Term Debt to Capital Metsera Therapeutics|MTSR - Company Aggregate Debts|Debt to Book Capitalization Ratio Metsera Inc|MTSR - Company Long-Term Debt|Short-Term Debt Metsera|Quick Liquidity metsera.com
- company profitability and valuation multiples indicators:
MTSR - Net Profit|Company Profit Forecast Metsera Inc|MTSR - Price to Earnings Ratio|Market Cap to Projected Earnings Metsera, Inc.|MTSR - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Metsera Inc|MTSR - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Metsera|MTSR - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months metsera.com|MTSR - Net earnings per share growth this year|Projected earnings per share increase next year Metsera Inc
Summary company analysis:metsera.com
Finished products of Metsera Corp

Metsera Inc (MTSR) seeks dominance in the high-margin obesity treatment segment through the aggressive development of an innovative R&D pipeline. The ratio of market capitalization to net income, reflected by the issuer's P/E multiple, quantifies investor expectations regarding future cash flows, separating the objective business value from speculative belief in a technological breakthrough, which allows for an assessment of the premium paid for growth potential.

Analysis of competing companies

P/E Multiple ascendispharma.com|Price to Earnings Ratio MDGL (Madrigal Pharmaceuticals, Inc.)|CORT (Corcept Therapeutics Inc.) - Company Value to Net Income|Price to Earnings Ratio Rhythm Pharmaceuticals Inc RYTM|AKRO - Price to Earnings Ratio|MoonLake Immunotherapeutics - P/E Multiple|Market Cap to Earnings crinetics.com|NAMS (NewAmsterdam Pharma Company N.V.) - Price to Earnings Ratio|SLNO: Market Price to Net Income Ratio|FOLD (Amicus Pharma) - P/E Multiple|P/E Multiple 89bio Pharma|P/E Multiple AGIO|Price to Earnings Ratio GPCR (structuretx.com)|Price to Earnings Ratio MiMedx MDXG|Rezolute Inc (RZLT) - Market Cap to Earnings|LXRX - Price to Earnings Ratio|MBX: Price to Earnings Ratio|ALT: P/E Multiple|AARD - Business Payback Period|Price to Earnings Ratio Sagimet Biosciences Inc.|BioAge Labs (BIOA) - Business Payback Period|Price to Earnings Ratio Biomea (BMEA)|Price to Earnings Ratio quincetx.com QNCX|Price to Earnings Ratio Fractyl Health, Inc. GUTS|VTVT - Price to Earnings Ratio|Agape ATP Corp. - P/E Multiple|Market Cap to Earnings Pluri Inc.|SYBX (synlogictx.com) - Price to Earnings Ratio|LPCN: Market Price to Net Income Ratio|Price to Earnings Ratio Matinas BioPharma Holdings, Inc.|sprucebiosciences.com (SPRB) - Business Payback Period|P/E Multiple GLTO|CTCX - Market Cap to Earnings|Price to Earnings Ratio Lumos Pharma Corp LUMO|Company Value to Net Income ONVO|Radius Recycling, Inc. - P/E Multiple